New treatment approaches for prostate cancer based on peptide analogues (Q37059390)

18 August 2017

1 reference

title

New treatment approaches for prostate cancer based on peptide analogues (English)

1 reference

18 August 2017

1 reference

Andrew V Schally

1 reference

18 August 2017

Bob Djavan

1 reference

18 August 2017

Anton Stangelberger

1 reference

18 August 2017

language of work or name

English

0 references

publication date

26 December 2007

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

890-900

1 reference

Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.

18 August 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Peptide analogs in the therapy of prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

The current state of hormonal therapy for prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Hypothalamic hormones and cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Molecular pharmacology of somatostatin receptor subtypes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotropin releasing hormone (GnRH) receptor antagonist "azaline B".

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Development of prostate cancer treatment: the good news

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

The development of androgen-independent prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Cytotoxic chemotherapy for prostate cancer: Who and when?

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Bombesin stimulates growth of human prostatic cancer cells in vitro

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Future prospects in prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone Agonist

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.EURURO.2007.12.021

Identifiers

DOI

10.1016/J.EURURO.2007.12.021

1 reference

release_da7mtyr42vbb3fw6bwayqdgaue

18 August 2017

Fatcat ID

1 reference

https://api.fatcat.wiki/v0/release/da7mtyr42vbb3fw6bwayqdgaue

Fatcat

reference URL

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference